Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 23Glioblastoma 13Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Prostatic Neoplasms 9Neoplasms 9Breast Neoplasms 9Brain Neoplasms 9Neoplasm Metastasis 8Kidney Neoplasms 8Gliosarcoma 8Melanoma 7Sarcoma 6Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Oligodendroglioma 5Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Glioma 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Lymphoma, B-Cell, Marginal Zone 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Rhabdomyosarcoma 3Osteosarcoma 3

Interventions

Paclitaxel 4Carboplatin 4Pemetrexed 2Palliative Care 2Gemcitabine 2temsirolimus 1rucaparib 1pembrolizumab 1niraparib 1nintedanib 1nilotinib 1liposomal doxorubicin 1fosaprepitant 1atezolizumab 1argatroban 1Topotecan 1Thrombopoietin 1Palonosetron 1Ocoxin 1Laparoscopy 1Heparin, Low-Molecular-Weight 1Filgrastim 1Electrocardiography 1Educational Status 1Dexamethasone 1Darbepoetin alfa 1Cognitive Behavioral Therapy 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Genital Neoplasms, Female × temsirolimus × Clear all
NCT00523432 2013-09-05

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

University of Chicago

Phase 1 Completed
15 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡